Act 4 Formulacion de La Hipotesis
Act 4 Formulacion de La Hipotesis
Act 4 Formulacion de La Hipotesis
Matricula: 145234
Grupo: SD29
Hipótesis o supuestos
2. Aaltonen KJ, Virkki LM, Malmivaara A, et al. Systematic review and meta-
analysis of the efficacy and safety of existing TNF blocking agents in treatment of
rheumatoid arthritis. PLoSOne. 2012; 7(1):e30275. Epub 2012 Jan 17.
5. Bori SG, Hernández Cruz B, Gobbo Montoya M, et al. Uso apropiado de los
antiinflamatorios no esteroideos en reumatología: documento de consenso de la
Sociedad Española de Reumatología y el Colegio Mexicano de Reumatología.
Reumatol Clin 2009; 5:3-12.
6. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis
refractory to anti-tumor necrosis factor therapy: Results of a multicenter,
randomized, double blind, placebo-controlled, phase III trial evaluating primary
efficacy and safety at twenty-four weeks. Arthritis Rheum 2010; 54:2793-2806.
7. Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the
management of early arthritis: report of a task force of the European Standing
Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann
RheumDis 2011; 66:34-45.